Technical Analysis for PTLA - Portola Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 27.55 -2.20% -0.62
PTLA closed down 2.2 percent on Friday, September 21, 2018, on 1.59 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical PTLA trend table...

Date Alert Name Type % Chg
Sep 21 Bollinger Band Squeeze Range Contraction 0.00%
Sep 21 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Sep 21 BB Squeeze Started Range Contraction 0.00%
Sep 21 Lower Bollinger Band Touch Weakness 0.00%
Sep 20 Fell Below 20 DMA Bearish -2.20%
Sep 20 Outside Day Range Expansion -2.20%
Sep 19 Crossed Above 20 DMA Bullish -3.77%
Sep 19 NR7 Range Contraction -3.77%
Sep 18 Fell Below 20 DMA Bearish -2.51%
Sep 17 Outside Day Range Expansion -2.99%

Older signals for PTLA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of thrombosis, other hematologic disorders, and inflammation. Its development products include Betrixaban, an oral once-daily inhibitor of Factor Xa, which is in Phase III development trials for the treatment of venous thromboembolism prophylaxis in acute medically ill patients; and PRT4445, a recombinant protein that is in Phase II trials to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. The company's products under development also comprise PRT2070, which is in Phase I/II studies to treat B-cell hematologic cancers; and PRT2607 that is in Phase I clinical trials for inflammatory disorders. It has a license and collaboration agreement with Biogen Idec Inc. for the development and commercialization of its clinical-stage product candidates PRT2607; license and collaboration agreement with Aciex Therapeutics, Inc. to co-develop and co-commercialize PRT2070 and related compounds for nonsystemic indications; and an agreement with Astellas Pharma, Inc. to research, develop, and commercialize Syk inhibitors. The company was founded in 2003 and is headquartered in South San Francisco, California.
Is PTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 56.7
52 Week Low 24.63
Average Volume 1,506,013
200-Day Moving Average 39.5166
50-Day Moving Average 32.1162
20-Day Moving Average 28.6485
10-Day Moving Average 28.523
Average True Range 1.3495
ADX 15.71
+DI 17.4148
-DI 23.9038
Chandelier Exit (Long, 3 ATRs ) 26.1915
Chandelier Exit (Short, 3 ATRs ) 29.1885
Upper Bollinger Band 29.9165
Lower Bollinger Band 27.3805
Percent B (%b) 0.07
BandWidth 8.852121
MACD Line -0.8071
MACD Signal Line -1.025
MACD Histogram 0.2179
Fundamentals Value
Market Cap 1.59 Billion
Num Shares 57.6 Million
EPS -4.55
Price-to-Earnings (P/E) Ratio -6.05
Price-to-Sales 85.78
Price-to-Book 24.64
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 29.47
Resistance 3 (R3) 29.58 29.06 29.15
Resistance 2 (R2) 29.06 28.57 29.00 29.04
Resistance 1 (R1) 28.30 28.27 28.04 28.19 28.94
Pivot Point 27.78 27.78 27.65 27.72 27.78
Support 1 (S1) 27.02 27.29 26.76 26.91 26.16
Support 2 (S2) 26.50 26.99 26.44 26.06
Support 3 (S3) 25.74 26.50 25.95
Support 4 (S4) 25.63